Zacks Research upgraded shares of Ardent Health (NYSE:ARDT – Free Report) from a strong sell rating to a hold rating in a report issued on Wednesday morning,Zacks.com reports.
ARDT has been the topic of a number of other reports. JPMorgan Chase & Co. reduced their price objective on shares of Ardent Health from $12.00 to $11.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 20th. UBS Group lowered their target price on shares of Ardent Health from $14.50 to $14.00 and set a “buy” rating for the company in a research note on Thursday, December 18th. Weiss Ratings restated a “sell (d)” rating on shares of Ardent Health in a report on Monday, December 29th. Royal Bank Of Canada cut their price target on shares of Ardent Health from $14.00 to $13.00 and set an “outperform” rating on the stock in a research report on Monday, March 9th. Finally, Leerink Partners decreased their price target on Ardent Health from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Friday, March 6th. Seven equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $14.25.
Check Out Our Latest Analysis on ARDT
Ardent Health Price Performance
Ardent Health (NYSE:ARDT – Get Free Report) last announced its earnings results on Wednesday, March 4th. The company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.35 by ($0.03). Ardent Health had a net margin of 2.15% and a return on equity of 14.30%. The company had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. As a group, equities research analysts anticipate that Ardent Health will post 1.23 earnings per share for the current year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in ARDT. Caitong International Asset Management Co. Ltd increased its position in shares of Ardent Health by 1,177.7% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,862 shares of the company’s stock worth $25,000 after acquiring an additional 2,638 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in Ardent Health in the 3rd quarter valued at about $61,000. KLP Kapitalforvaltning AS bought a new position in Ardent Health in the 3rd quarter valued at about $80,000. New York State Common Retirement Fund boosted its stake in Ardent Health by 121.4% during the 2nd quarter. New York State Common Retirement Fund now owns 6,200 shares of the company’s stock valued at $85,000 after purchasing an additional 3,400 shares during the last quarter. Finally, State of Alaska Department of Revenue acquired a new position in Ardent Health during the 3rd quarter valued at about $103,000.
Ardent Health Company Profile
Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.
Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.
Read More
Receive News & Ratings for Ardent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardent Health and related companies with MarketBeat.com's FREE daily email newsletter.
